1. 366PActivity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours. (24th November 2019) Authors: Ziegler, D S; Doz, F; Geoerger, B; Dubois, S; Grilley-Olson, J E; van Tilburg, C; Italiano, A; Lissat, A; Kang, J-H; Tahara, M; Boni, V; Perreault, S; Capra, M; Nanda, S; Brega, N; Holynskyj, A; Hong, D S; Hyman, D; Drilon, A Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 930TiPPhase II/III study of rogaratinib versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma selected based on FGFR1/3 mRNA expression. (23rd October 2018) Authors: Sternberg, C N; Bellmunt, J; Nishiyama, H; Petrylak, D P; Quinn, D I; Nakajima, K; Lu, C; Holynskyj, A Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗